EUVIMEDEUVIMED entdecken
Crossref

Targeting inflammatory dysregulation in metabolic dysfunction-associated steatotic liver disease rat model: the preventive and therapeutic effects of acetyl-11-keto-beta-boswellic acid

Sajad Ehtiati, Roya Pakrad, Seyyed Hossein Khatami, Reza Ataei Kachouei, Alireza Doagoo, Hossein Lanjanian, Seyyed Amir Hossein Ghazizadeh Hashemi, Nastaran Hamed, Behzad Hatami, Reyhane Ahmadzade, Farzaneh Salmani, Saeed Karima

Naunyn-Schmiedeberg's Archives of Pharmacology · 2025

DOI: 10.1007/s00210-025-04340-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2025. Verfasst von Sajad Ehtiati und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Biochemistry, School of Medicine, Shahid Beheshti University of Medical Sciences (SBMU), Tehran, Iran. Hauptthemen laut MEDLINE: Triterpenes, Anti-Inflammatory Agents, Fatty Liver, Non-alcoholic Fatty Liver Disease. Die Arbeit nennt 51 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic associated fatty liver disease (MASLD) is a global health issue affecting over 30% of the population and can progress to severe liver conditions such as cirrhosis and hepatocellular carcinoma (HCC). The progression of MASLD is driven by underlying metabolic dysregulation and chronic inflammation. This study aims to evaluate the therapeutic efficacy of acetyl-11-keto-β-boswellic acid (AKBA) in a rat model of MASLD induced by a high-fat and high-fructose diet (HFrD). We hypothesize that AKBA supplementation will suppress pro-inflammatory cytokine expression and inhibit inflammatory signaling pathways, thereby ameliorating MASLD progression. MASLD was induced in 36 male rats, randomly divided into two main groups: prevention (6-week regimen) and treatment (8-week regimen). Each group was further divided into three subgroups: Control, HFrD, and AKBA. In the prevention group, the subgroup receiving a high-fat, high-fructose diet (HFrD) was simultaneously administered AKBA. In the treatment group, after inducing MASLD with HFrD, AKBA was administered as a therapeutic intervention. Serum levels of IL-2, pro-inflammatory cytokines (IL-1β, IL-18, IL-1α), and anti-inflammatory cytokines (IL-1Ra, IL-10) were measured using ELISA. Additionally, IL-1R1 gene expression was analyzed using quantitative real-time PCR. Histological examinations of liver tissues were conducted to assess triglyceride accumulation. AKBA significantly reduced serum levels of pro-inflammatory cytokines, including IL-1α, IL-1β, and IL-18, which are key products of the NLRP3 inflammasome complex, as well as reduced IL-2 serum levels. It also increased levels of the anti-inflammatory cytokines IL-1Ra and IL-10. Additionally, AKBA mitigated weight gain and decreased triglyceride accumulation in liver tissues compared to the HFrD group. AKBA exhibits potent anti-inflammatory properties that ameliorate MASLD by reducing hepatic steatosis and inflammatory markers. Further studies, including extended durations and human clinical trials, are warranted to fully elucidate AKBA's therapeutic potential.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TriterpenesAnti-Inflammatory AgentsFatty LiverNon-alcoholic Fatty Liver DiseaseAnimalsMaleDisease Models, AnimalCytokinesRatsDiet, High-FatFructoseRats, Sprague-DawleyLiverInflammationInflammation Mediators

Stichwörter der Autor:innen

Acetyl-11-keto-β-boswellic acid (AKBA)Anti-Inflammatory cytokinesInflammationMetabolic associated fatty liver disease (MASLD)NLRP3 inflammasomePro-Inflammatory cytokines

Substanzen

Triterpenesacetyl-11-ketoboswellic acidCytokinesAnti-Inflammatory AgentsFructoseInflammation Mediators

Autor:innen und Institutionen

  • Department of Clinical Biochemistry, School of Medicine, Shahid Beheshti University of Medical Sciences (SBMU), Tehran, Iran.
  • Cellular and Molecular Endocrine Research Center, Research Institute for Endocrine Molecular Biology, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Department of Otorhinolaryngology, School of Medicine Hearing Disorders Research Center, Loghman Hakim Hospital Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Department of Clinical Biochemistry, School of Medicine, Shahid Beheshti University of Medical Sciences (SBMU), Tehran, Iran. saeed.karima@sbmu.ac.ir.

Zitieren

APA

Ehtiati, S., Pakrad, R., Khatami, S. H., Kachouei, R. A., Doagoo, A., Lanjanian, H., Ghazizadeh Hashemi, S. A. H., Hamed, N., Hatami, B., Ahmadzade, R., Salmani, F., & Karima, S. (2025). Targeting inflammatory dysregulation in metabolic dysfunction-associated steatotic liver disease rat model: the preventive and therapeutic effects of acetyl-11-keto-beta-boswellic acid. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-025-04340-3

Vancouver

Ehtiati S, Pakrad R, Khatami SH, Kachouei RA, Doagoo A, Lanjanian H, et al. Targeting inflammatory dysregulation in metabolic dysfunction-associated steatotic liver disease rat model: the preventive and therapeutic effects of acetyl-11-keto-beta-boswellic acid. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025. doi:10.1007/s00210-025-04340-3

BibTeX
@article{Ehtiati2025,
  author = {Ehtiati, Sajad and Pakrad, Roya and Khatami, Seyyed Hossein and Kachouei, Reza Ataei and Doagoo, Alireza and Lanjanian, Hossein and Ghazizadeh Hashemi, Seyyed Amir Hossein and Hamed, Nastaran and Hatami, Behzad and Ahmadzade, Reyhane and Salmani, Farzaneh and Karima, Saeed},
  title = {Targeting inflammatory dysregulation in metabolic dysfunction-associated steatotic liver disease rat model: the preventive and therapeutic effects of acetyl-11-keto-beta-boswellic acid},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2025},
  doi = {10.1007/s00210-025-04340-3}
}
Kostenlos starten →